Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652949 · ClinicalTrials.gov registry record · NA
Valiant Evo US Clinical Trial
A NA study, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT02652949 is a NA study that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 100 participants.
The verdict
NCT02652949, a NA study, has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the Valiant Evo US Clinical Trial is to demonstrate the safety and effectiveness of the Valiant Evo Thoracic Stent Graft System in subjects with a descending thoracic aortic aneurysm (DTAA) who are candidates for endovascular repair.
Interventions
- DEVICE Valiant Evo Thoracic Stent Graft System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-04 |
| Est. Completion | 2023-03-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652949
The ClinicalTrials.gov registry entry for NCT02652949 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valiant Evo Thoracic Stent Graft System is the first listed.
NCT02652949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02652949 about?
NCT02652949 is a clinical study titled "Valiant Evo US Clinical Trial". The purpose of the Valiant Evo US Clinical Trial is to demonstrate the safety and effectiveness of the Valiant Evo Thoracic Stent Graft System in subjects with a descending thoracic aortic aneurysm (DTAA) who are candidates for endovascular repair.
What is the current status of trial NCT02652949?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2016-04. Estimated completion is 2023-03-02.
What interventions are being tested in trial NCT02652949?
The interventions under investigation include: Valiant Evo Thoracic Stent Graft System (DEVICE).
Who is sponsoring clinical trial NCT02652949?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.